10.11.2022 - - Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 – - Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6 Deficiency on track for the first quarter of 2023 – .
BOSTON, Sept. 06, 2022 Inozyme Pharma, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte,. | September 6, 2022
15.08.2022 - - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - .
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights - Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway - . | March 15, 2022